SCHEMBL12633864

SCHEMBL12633864

CCOC(=O)CCCCN1CCN(c2cccc(-c3ccc4c(c3)C(C)(C)CCC4(C)C)n2)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RARA P10276 2/20 0.45
RARB P10826 2/20 0.45
RARG P13631 2/20 0.40
HTR1A P08908 6/20 0.40
HTR2A P28223 6/20 0.40
DRD3 P35462 5/20 0.40
HTR2C P28335 3/20 0.40
DRD2 P14416 1/20 0.40
DRD4 P21917 1/20 0.40
HTR7 P34969 1/20 0.40
ALOX5AP P20292 1/20 0.39
KCNH2 Q12809 2/20 0.39
PIM1 P11309 1/20 0.38
PIM2 Q9P1W9 1/20 0.38
CNR1 P21554 1/20 0.38
FFAR4 Q5NUL3 1/20 0.38
CHRM1 P11229 1/20 0.38
SLC6A2 P23975 1/20 0.38
HRH2 P25021 1/20 0.38
HRH1 P35367 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2016847 0.88 RARA (0.51) RARARARBRARGHTR1AHTR2A
SCHEMBL12959534 0.87 RARA (0.44) RARARARBRARGHTR1AHTR2A
SCHEMBL2014838 0.86 RARA (0.46) RARARARBHTR1AHTR2ADRD3
SCHEMBL12633656 0.85 RARA (0.45) RARARARBRARGHTR1AHTR2A
SCHEMBL2017424 0.85 RARB (0.52) RARARARBRARGHTR1AHTR2A
SCHEMBL2223236 0.85 MAPT (0.48) RARARARBRARG
SCHEMBL2011986 0.85 RARA (0.47) RARARARBRARGHTR1AHTR2A
SCHEMBL12633279 0.84 RARA (0.43) RARARARBHTR1AHTR2ADRD3
SCHEMBL12632583 0.84 HTR1A (0.45) RARARARBHTR1AHTR2ADRD3
SCHEMBL12633167 0.84 RARA (0.47) RARARARBRARGHTR1AHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9062015-B2 Inhibitors of sphingosine kinase MERCK PATENT GMBH (DE) 2015-06-23 US disclosed
US-9062015-B2 Inhibitors of sphingosine kinase MERCK PATENT GMBH (DE) 2015-06-23 US disclosed
EP-2513057-B1 SPHINGOSINE KINASE INHIBITORS MERCK PATENT GMBH (DE) 2013-09-04 EP disclosed
US-20120252789-A1 INHIBITORS OF SPHINGOSINE KINASE MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2012-10-04 US disclosed
US-20120252789-A1 INHIBITORS OF SPHINGOSINE KINASE MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2012-10-04 US disclosed
WO-2011072791-A1 SPHINGOSINE KINASE INHIBITORS MERCK PATENT GMBH (DE) 2011-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120252789-A1 INHIBITORS OF SPHINGOSINE KINASE SPHK1, SPHK2, S1PR3 RARA 4373/4885RARB 4194/4885RARG 4187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.